Clinical Fellowships
Supports U.S. academic institutions in training physicians through fellowships focused on the diagnosis, treatment, and research of Transthyretin-mediated (ATTR) Amyloidosis.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026 (Clinical Fellowships submission deadline)
Funding Amounts: Up to $95,000 per institution for a one-year fellowship; funds support fellow salary and benefits only.
Summary: Supports U.S. academic institutions to train physicians in the diagnosis, treatment, and research of Transthyretin-mediated (ATTR) Amyloidosis through clinical fellowship programs.
Key Information: Awards are made to institutions, not individuals; only ACGME-accredited U.S. institutions with active Cardiology Fellowship programs are eligible.
Description
Alnylam Pharmaceuticals' Clinical Fellowships program provides funding to support educational clinical programs within U.S. healthcare academic organizations. The primary focus is on mentoring and advancing physician training in the diagnosis, treatment, and research of Transthyretin-mediated (ATTR) Amyloidosis. The program encourages multidisciplinary collaboration to improve early recognition, optimize treatment pathways, and accelerate the translation of emerging science into high-quality, patient-centered care. Grants are awarded directly to eligible institutions, supporting the development of robust fellowship curricula and ensuring fellows gain experience in both clinical care and research related to ATTR Amyloidosis.
